title: Cutaneous castleman's disease responds to anti interleukin-6 treatment.
abstract: Castleman's disease is uncommon, and cutaneous involvement is even rarer. We report a 42-year-old Asian woman with the multicentric plasma cell variant of Castleman's disease limited to her skin. The literature suggests that Castleman's disease is driven by interleukin-6 (IL-6). Based on these data, we hypothesized that suppression of IL-6 would have a salutary effect. Therefore, our patient was treated with CNTO328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses.
authors.affiliation: Phase I Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, TX 77030, USA. rkurzroc@mdanderson.org
authors.forename: Bilal
authors.initials: B
authors.lastname: Ahmed
authors.forename: Jaime A
authors.initials: JA
authors.lastname: Tschen
authors.forename: Philip R
authors.initials: PR
authors.lastname: Cohen
authors.forename: Mohamed H
authors.initials: MH
authors.lastname: Zaki
authors.forename: Peter L
authors.initials: PL
authors.lastname: Rady
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Tyring
authors.forename: Robert E
authors.initials: RE
authors.lastname: Corringham
authors.forename: Razelle
authors.initials: R
authors.lastname: Kurzrock
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D005871:Castleman Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D010950:Plasma Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D015850:Interleukin-6